Biochemical validation of a rat model for polycystic kidney disease: Comparison of guanidino compound profile with the human condition

Kidney International

Volumn 69, Issue 11, 2006, Pages 2003-2012

  Torremans, A ^a   Marescau, B ^a   Kranzlin B ^b   Gretz, N ^b   Billiouw, J M ^c   Vanholder, R ^d   De Smet, R ^d   Bouwman, K ^e   Brouns, R ^a,e   De Deyn, P P ^a,e  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c OLV HOSPITAL   (Belgium)

^d GHENT UNIVERSITY HOSPITAL   (Belgium)

^e MIDDELHEIM HOSPITAL   (Belgium)

Author keywords

ADMA; Guanidino compounds; PKD; PKD Mhm rat model; Polycystic kidney disease; SDMA

Indexed keywords

GUANIDINE DERIVATIVE; GUANIDINOSUCCINIC ACID; METHYLGUANIDINE; N(G),N(G) DIMETHYLARGININE; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DIALYSIS; GENOTYPE; GLOMERULUS FILTRATION RATE; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY POLYCYSTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; RAT; SERUM; UREA BLOOD LEVEL; URINARY EXCRETION; URINE LEVEL;

ANIMALS; DISEASE MODELS, ANIMAL; GLYCINE; GUANIDINES; HUMANS; POLYCYSTIC KIDNEY DISEASES; RATS; RATS, SPRAGUE-DAWLEY; SUCCINATES;

EID: 33745228058     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5000443     Document Type: Article

References (37)

1. Wilson P. Polycystic kidney disease. N Engl J Med 2004; 350: 151-164.
2. Ringoir S, Schoots A, Vanholder R. Uremic toxins. Kidney Int 1988; 33(Suppl 24): S4-S9.
3. Vanholder R, De Smet R. Pathophysiologic effects of uremic retention solutes. J Am Soc Nephrol 1999; 10: 1815-1823.
4. Vanholder RC, Glorieux G, De Smet R, De Deyn PP. Low water-soluble uremic toxins. Adv Ren Replace Ther 2003; 10: 257-269.
5. Hanai T, Inamaoto Y, Inamoto S. Chromatography of guanidino compounds. J Chromatogr B 2000; 747: 123-138.
6. Hörl W. Uremic toxins: new aspects. J Nephrol 2000; 13: S83-S88.
7. Brouns R, De Deyn PP. Neurological complications in renal failure: a review. Clin Neurol Neurosurg 2004; 107: 1-16.
8. De Deyn PP, Macdonald R. Guanidino compounds that are increased in cerebrospinal fluid and brain of uremic patients inhibit GABA and glycine response on mouse neurons in cell culture. Ann Neurol 1990; 28: 627-632.
9. D'Hooge R, Pei Y, Marescau B, De Deyn PP. Behavioral toxicity of guanidinosuccinic acid in adult and young mice. Toxicol Lett 1992; 64-65: 773-777.
10. D'Hooge R, De Deyn PP, Van de Vijver G et al. Uraemic guanidino compounds inhibit gamma-aminobutyric acid-evoked currents in mouse spinal cord neurones. Neurosci Lett 1999; 265: 83-86.
11. De Deyn PP, Saxena V, Abts H et al. Clinical and pathophysiological aspects of neurological complications in renal failure. Acta Neurol Belg 1992; 92: 191-206.
12. Marescau B, Nagels G, Possemiers I et al. Guanidino compounds in serum and urine of nondialysed patients with chronic renal insufficiency. Metabolism 1997; 46: 1024-1031.
13. Vallance P, Leone A, Calver A et al. Endogenous dimethylarginine as an inhibitor of nitric oxide synthase. J Cardiovasc Pharmacol 1992; 20: S60-S62.
14. Faraci FM, Brian JE, Heistad DD. Response of cerebral blood vessels to an endogenous inhibitor of nitric oxide synthase. Am J Physiol 1995; 269: H1522-H1527.
15. Segarra G, Medina P, Ballester RM et al. Effects of some guanidine compounds on human cerebral arteries. Stroke 1999; 30: 2206-2210.
16. Glorieux G, Dhondt A, Jacobs P et al. In vitro study of the potential role of guanidines in leukocyte functions related to atherogenesis and infection. Kidney Int 2004; 65: 1-9.
17. Levillain O, Marescau B, De Deyn PP. Guanidino compound metabolism in rats subjected to 20 and 90% nephrectomy. Kidney Int 1995; 47: 464-472.
18. Al Banchaabouchi M, Marescau B, D'Hooge R et al. Biochemical and histochemical changes in nephrectomized mice. Metabolism 1998; 47: 355-361.
19. G- dimethylarginine in renal insufficiency. Pflügers Arch-Eur J Physiol 2000; 439: 524-531.
20. Gattone V, Grantham J. Understanding human cystic disease trough experimental models. Semin Nephrol 1991; 11: 617-631.
21. Gretz N, Hocker A, Bauer S et al. Rat models of polycystic kidney disease. Contrib Nephrol 1992; 97: 35-46.
22. Kaspareit-Rittinghausen J, Deerberg F, Wcislo A. Hereditary polycystic kidney disease: adult polycystic kidney disease associated with renal hypertension, renal osteodystrophy, and uremic enteritis in SPRD rats. Am J Pathol 1991; 139: 693-696.
23. Bihoreau M, Ceccherini I, Browne J et al. Location of the first genetic locus, PKDr1, controlling autosomal dominant polycystic kidney disease in Han:SPRD. Hum Mol Genet 1997; 6: 609-613.
24. Gretz N, Ceccherini I, Kränzlin B et al. Gender-dependent disease severity in autosomal polycystic kidney disease of rats. Kidney Int 1995; 48: 496-500.
25. Cowley B, Gudapaty S, Kraybill A et al. Autosomal-dominant polycystic kidney disease in the rat. Kidney Int 1993; 43: 522-534.
26. Schäfer K, Gretz N, Bader M et al. Characterization of the Han:SPRD rat model for hereditary polycystic kidney disease. Kidney Int 1994; 46: 134-152.
27. De Deyn PP, D'Hooge R, Van Bogaert PP, Marescau B. Endogenous guanidino compounds as uremic neurotoxins. Kidney Int 2001; 59: S77-S83.
28. Marescau B, De Deyn PP, Qureshi I et al. The pathobiochemistry of uremia and hyperargininemia further demonstrates a metabolic relationship between urea and guanidinosuccinic acid. Metabolism 1992; 41: 1021-1024.
29. Natelson S, Sherwin J. Proposed mechanism for urea nitrogen re-utilization: relationship between urea and proposed guanidine cycles. Clin Chem 1979; 25: 1343-1344.
30. Marescau B, De Deyn PP, Holvoet J et al. Guanidino compounds in serum and urine of cirrhotic patients. Metabolism 1995; 44: 584-588.
31. Wyss M, Kaddurah-Daouk R. Creatine and creatine metabolism. Physiol Rev 2000; 80: 1107-1213.
32. Levillain O, Hus-Citharel A, Morel F, Bankir L. Localization of arginine synthesis along rat nephron. Am J Physiol 1990; 259: F916-F923.
33. McGuire DM, Gross MD, Elde RP, Van Pilsum JF. Localization of L-arginine-glycine amidinotransferase protein in rat tissues by immunofluorescence microscopy. J Histochem Cytochem 1986; 34: 429-435.
34. Kuroda M. Study on impaired metabolism of guanidinoacetic acid in chronic renal failure rabbits with special reference to impaired conversion of arginine to guanidinoacetic acid. Nephron 1993; 65: 605-611.
35. Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999; 130: 461-470.
36. Levey AS. Nondiabetic kidney disease. N Engl J Med 2002; 347: 1505-1511.
37. Ceriotti G. Ultramicro determination of plasma urea by reaction with diacetylmonoxime-antipyrine without deproteinization. Clin Chem 1971; 17: 400-402.